Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03349710 · ClinicalTrials.gov registry record · Phase 3
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 74
- Enrollment target
NCT03349710 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 74 participants.
The verdict
NCT03349710, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 74 participants
- Enrollment target
Study Summary
This study has two, independent, cohorts, both in locally advanced squamous cell head and neck cancer. The purpose of the first cohort is to determine whether nivolumab in combination with radiotherapy is more effective than cetuximab in combination with radiotherapy, in subjects who are ineligible for cisplatin. The purpose of the second cohort is to determine whether nivolumab, cisplatin, and radiotherapy is more effective than cisplatin and radiotherapy in subjects who are eligible to receive cisplatin
Interventions
- DRUG Cisplatin
- RADIATION Radiotherapy
- DRUG Cetuximab
- BIOLOGICAL Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2017-12-15 |
| Est. Completion | 2019-10-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03349710
The ClinicalTrials.gov registry entry for NCT03349710 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT03349710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03349710 about?
NCT03349710 is a clinical study titled "Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer". This study has two, independent, cohorts, both in locally advanced squamous cell head and neck cancer. The purpose of the first cohort is to determine whether nivolumab in combination with radiotherapy is more effective than cetuximab in combination with radiotherapy, in subjects who are ineligible ...
What is the current status of trial NCT03349710?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 74 participants. The study started on 2017-12-15. Estimated completion is 2019-10-14.
What interventions are being tested in trial NCT03349710?
The interventions under investigation include: Cisplatin (DRUG), Radiotherapy (RADIATION), Cetuximab (DRUG), Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03349710?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.